Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.42 |
| ▸ | STK10 | O94804 | 2/20 | 0.41 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410792 | 0.91 | GABRA1 (0.56) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4413427 | 0.88 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4708486 | 0.84 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4707943 | 0.83 | GABRA1 (0.56) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4707924 | 0.83 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4708568 | 0.83 | GABRA1 (0.50) | CYP11B1CYP11B2CYP19A1CYP3A4GABRA1 | |
| SCHEMBL4415166 | 0.82 | STK10 (0.45) | CYP11B1CYP11B2CYP19A1STK10SLK | |
| SCHEMBL4710649 | 0.82 | GABRA1 (0.52) | CYP3A4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4410915 | 0.80 | GABRA1 (0.46) | CYP3A4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4415391 | 0.80 | STK10 (0.43) | CYP11B1CYP11B2CYP19A1GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2009-08-27 | — | — | US | claimed |
| EP-1749824-A1 | Benzodiazepine derivatives, their preparation and the therapeutic use thereof | NEURO3D (FR) | 2007-02-07 | — | — | EP | claimed |
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2009-08-27 | — | — | US | disclosed |
| EP-1910315-A2 | BENZODIAZEPINE DERIVATIVES, THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007026254-A2 | BENZODIAZEPINE DERIVATIVES , THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2007-03-08 | — | — | WO | disclosed |
| EP-1749824-A1 | Benzodiazepine derivatives, their preparation and the therapeutic use thereof | NEURO3D (FR) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | PDE12, PDE4B, PDE2A | CYP11B1 31/4885CYP11B2 16/4885CYP19A1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.